
Sign up to save your podcasts
Or
This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing.
In this episode, Fierce Pharma’s Fraiser Kansteiner is joined by Bruce Levine, Ph.D., who is the co-inventor of Kymriah and the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania. He’s also joined by executives from CGT technology provider ScaleReady and regenerative cell therapy developer CellProthera.
They dive into novel production approaches discussed earlier in this series, with a special focus on CAR-T therapies.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
3.8
88 ratings
This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing.
In this episode, Fierce Pharma’s Fraiser Kansteiner is joined by Bruce Levine, Ph.D., who is the co-inventor of Kymriah and the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania. He’s also joined by executives from CGT technology provider ScaleReady and regenerative cell therapy developer CellProthera.
They dive into novel production approaches discussed earlier in this series, with a special focus on CAR-T therapies.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
235 Listeners
8,582 Listeners
380 Listeners
446 Listeners
1,779 Listeners
1,443 Listeners
124 Listeners
314 Listeners
1,276 Listeners
1,522 Listeners
84 Listeners
30 Listeners
143 Listeners
10 Listeners
74 Listeners